MedTrace Logo

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2020-06-16

No results posted yet for this study

Summary

The primary objective is to assess the impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses

DRUG

Placebo

Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses

Sponsors & Collaborators

  • WellStar Health System

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-07
Primary Completion
2020-12-07
Completion
2020-12-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429867 on ClinicalTrials.gov